VVOS Relative Valuation
VVOS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, VVOS is overvalued; if below, it's undervalued.
Historical Valuation
Vivos Therapeutics Inc (VVOS) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.70. The fair price of Vivos Therapeutics Inc (VVOS) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：2.13
Fair
-1.29
PE
1Y
3Y
5Y
Trailing
Forward
-2.37
EV/EBITDA
Vivos Therapeutics Inc. (VVOS) has a current EV/EBITDA of -2.37. The 5-year average EV/EBITDA is -0.72. The thresholds are as follows: Strongly Undervalued below -3.16, Undervalued between -3.16 and -1.94, Fairly Valued between 0.50 and -1.94, Overvalued between 0.50 and 1.72, and Strongly Overvalued above 1.72. The current Forward EV/EBITDA of -2.37 falls within the Undervalued range.
-1.60
EV/EBIT
Vivos Therapeutics Inc. (VVOS) has a current EV/EBIT of -1.60. The 5-year average EV/EBIT is -2.04. The thresholds are as follows: Strongly Undervalued below -6.91, Undervalued between -6.91 and -4.47, Fairly Valued between 0.40 and -4.47, Overvalued between 0.40 and 2.84, and Strongly Overvalued above 2.84. The current Forward EV/EBIT of -1.60 falls within the Historic Trend Line -Fairly Valued range.
0.69
PS
Vivos Therapeutics Inc. (VVOS) has a current PS of 0.69. The 5-year average PS is 2.10. The thresholds are as follows: Strongly Undervalued below -2.23, Undervalued between -2.23 and -0.07, Fairly Valued between 4.26 and -0.07, Overvalued between 4.26 and 6.43, and Strongly Overvalued above 6.43. The current Forward PS of 0.69 falls within the Historic Trend Line -Fairly Valued range.
-1.02
P/OCF
Vivos Therapeutics Inc. (VVOS) has a current P/OCF of -1.02. The 5-year average P/OCF is -3.04. The thresholds are as follows: Strongly Undervalued below -13.88, Undervalued between -13.88 and -8.46, Fairly Valued between 2.38 and -8.46, Overvalued between 2.38 and 7.80, and Strongly Overvalued above 7.80. The current Forward P/OCF of -1.02 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Vivos Therapeutics Inc. (VVOS) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.
Vivos Therapeutics Inc (VVOS) has a current Price-to-Book (P/B) ratio of 6.76. Compared to its 3-year average P/B ratio of 24.64 , the current P/B ratio is approximately -72.57% higher. Relative to its 5-year average P/B ratio of 16.04, the current P/B ratio is about -57.87% higher. Vivos Therapeutics Inc (VVOS) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -129.71%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -93.75% , the current FCF yield is about -100.00% lower.
7.02
P/B
Median3y
24.64
Median5y
16.04
-82.59
FCF Yield
Median3y
-129.71
Median5y
-93.75
Competitors Valuation Multiple
The average P/S ratio for VVOS's competitors is 0.00, providing a benchmark for relative valuation. Vivos Therapeutics Inc Corp (VVOS) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 75.73%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of VVOS decreased by 49.88% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 3.86M to 6.78M.
The secondary factor is the Margin Expansion, contributed 17.47%to the performance.
Overall, the performance of VVOS in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Vivos Therapeutics Inc (VVOS) currently overvalued or undervalued?
What is Vivos Therapeutics Inc (VVOS) fair value?
How does VVOS's valuation metrics compare to the industry average?
What is the current P/B ratio for Vivos Therapeutics Inc (VVOS) as of Dec 05 2025?
What is the current FCF Yield for Vivos Therapeutics Inc (VVOS) as of Dec 05 2025?
What is the current Forward P/E ratio for Vivos Therapeutics Inc (VVOS) as of Dec 05 2025?